RS67299B1 - Kompozicije za lečenje i/ili prevenciju bolesti agregacije proteina - Google Patents
Kompozicije za lečenje i/ili prevenciju bolesti agregacije proteinaInfo
- Publication number
- RS67299B1 RS67299B1 RS20250996A RSP20250996A RS67299B1 RS 67299 B1 RS67299 B1 RS 67299B1 RS 20250996 A RS20250996 A RS 20250996A RS P20250996 A RSP20250996 A RS P20250996A RS 67299 B1 RS67299 B1 RS 67299B1
- Authority
- RS
- Serbia
- Prior art keywords
- compositions
- treating
- preventing protein
- aggregation diseases
- aggregation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382439 | 2018-06-19 | ||
| EP22186334.3A EP4094754B1 (en) | 2018-06-19 | 2019-06-19 | Compositions for treating and/or preventing protein-aggregation diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS67299B1 true RS67299B1 (sr) | 2025-11-28 |
Family
ID=62716030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20250996A RS67299B1 (sr) | 2018-06-19 | 2019-06-19 | Kompozicije za lečenje i/ili prevenciju bolesti agregacije proteina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210251953A1 (sr) |
| EP (2) | EP3810128B1 (sr) |
| JP (2) | JP2021528442A (sr) |
| CN (2) | CN112601521A (sr) |
| AU (1) | AU2019291061B2 (sr) |
| BR (1) | BR112020026066A2 (sr) |
| CA (1) | CA3103834A1 (sr) |
| DK (1) | DK3810128T3 (sr) |
| ES (2) | ES3044215T3 (sr) |
| HR (1) | HRP20251214T1 (sr) |
| MX (1) | MX2020014070A (sr) |
| PL (1) | PL3810128T3 (sr) |
| PT (1) | PT3810128T (sr) |
| RS (1) | RS67299B1 (sr) |
| SM (1) | SMT202500382T1 (sr) |
| WO (1) | WO2019243453A1 (sr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| CN112601521A (zh) * | 2018-06-19 | 2021-04-02 | 帕布罗·德奥拉韦德大学 | 用于治疗和/或预防蛋白质聚集疾病的组合物 |
| EP3918323A4 (en) | 2019-01-30 | 2022-12-28 | TrueBinding, Inc. | ANTI-GAL3 ANTIBODIES AND USES THEREOF |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| EP3988096A1 (en) * | 2020-10-26 | 2022-04-27 | Universidad Pablo de Olavide OTRI | Sulfated c19 steroid hormones to treat and/or prevent proteotoxicity in protein-aggregation diseases |
| CN112552272B (zh) * | 2020-12-22 | 2023-06-27 | 四川大学 | 香豆素类化合物及其制备方法和应用、药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9603325D0 (en) | 1996-02-16 | 1996-04-17 | Imperial College | A compound |
| US5556847A (en) * | 1994-10-27 | 1996-09-17 | Duquesne University Of The Holy Ghost | Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors |
| JP4320089B2 (ja) * | 1999-07-06 | 2009-08-26 | あすか製薬株式会社 | フェニルスルファメート誘導体 |
| US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
| JP2003525903A (ja) * | 2000-03-03 | 2003-09-02 | エーザイ株式会社 | コリンエステラーゼ阻害剤の新規使用法 |
| GB0511190D0 (en) * | 2005-06-01 | 2005-07-06 | Sterix Ltd | Use |
| ES2514140B1 (es) * | 2013-03-26 | 2015-08-03 | Universidad Pablo De Olavide | Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento |
| CA2968094A1 (en) * | 2014-12-05 | 2016-06-09 | An2H Discovery Limited | Parkin ligase activation methods and compositions |
| AU2016343812A1 (en) | 2015-10-30 | 2018-05-10 | Ultragenyx Pharmaceutical Inc. | Methods and compositions for the treatment of amyloidosis |
| US10780094B2 (en) * | 2016-07-22 | 2020-09-22 | New York University | Use of carbonic anhydrase inhibitors for treatment of neurological and psychiatric disorders |
| CN112601521A (zh) * | 2018-06-19 | 2021-04-02 | 帕布罗·德奥拉韦德大学 | 用于治疗和/或预防蛋白质聚集疾病的组合物 |
-
2019
- 2019-06-19 CN CN201980054686.3A patent/CN112601521A/zh active Pending
- 2019-06-19 DK DK19730826.5T patent/DK3810128T3/da active
- 2019-06-19 ES ES22186334T patent/ES3044215T3/es active Active
- 2019-06-19 CA CA3103834A patent/CA3103834A1/en active Pending
- 2019-06-19 EP EP19730826.5A patent/EP3810128B1/en active Active
- 2019-06-19 AU AU2019291061A patent/AU2019291061B2/en active Active
- 2019-06-19 EP EP22186334.3A patent/EP4094754B1/en active Active
- 2019-06-19 PL PL19730826.5T patent/PL3810128T3/pl unknown
- 2019-06-19 ES ES19730826T patent/ES2931815T3/es active Active
- 2019-06-19 US US17/253,378 patent/US20210251953A1/en not_active Abandoned
- 2019-06-19 WO PCT/EP2019/066271 patent/WO2019243453A1/en not_active Ceased
- 2019-06-19 HR HRP20251214TT patent/HRP20251214T1/hr unknown
- 2019-06-19 MX MX2020014070A patent/MX2020014070A/es unknown
- 2019-06-19 RS RS20250996A patent/RS67299B1/sr unknown
- 2019-06-19 JP JP2020571600A patent/JP2021528442A/ja active Pending
- 2019-06-19 SM SM20250382T patent/SMT202500382T1/it unknown
- 2019-06-19 CN CN202410870792.1A patent/CN118845759A/zh active Pending
- 2019-06-19 PT PT197308265T patent/PT3810128T/pt unknown
- 2019-06-19 BR BR112020026066-5A patent/BR112020026066A2/pt unknown
-
2024
- 2024-02-22 JP JP2024025631A patent/JP2024059803A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES3044215T3 (en) | 2025-11-26 |
| ES2931815T3 (es) | 2023-01-02 |
| CN112601521A (zh) | 2021-04-02 |
| BR112020026066A2 (pt) | 2021-03-23 |
| WO2019243453A1 (en) | 2019-12-26 |
| EP4094754B1 (en) | 2025-08-06 |
| MX2020014070A (es) | 2021-05-27 |
| EP4094754C0 (en) | 2025-08-06 |
| JP2024059803A (ja) | 2024-05-01 |
| PL3810128T3 (pl) | 2023-01-30 |
| US20210251953A1 (en) | 2021-08-19 |
| EP4094754A1 (en) | 2022-11-30 |
| SMT202500382T1 (it) | 2025-11-10 |
| DK3810128T3 (da) | 2022-10-31 |
| PT3810128T (pt) | 2022-11-09 |
| AU2019291061A1 (en) | 2021-02-04 |
| CN118845759A (zh) | 2024-10-29 |
| CA3103834A1 (en) | 2019-12-26 |
| EP3810128B1 (en) | 2022-08-03 |
| JP2021528442A (ja) | 2021-10-21 |
| EP3810128A1 (en) | 2021-04-28 |
| AU2019291061B2 (en) | 2025-04-10 |
| HRP20251214T1 (hr) | 2025-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006627B (en) | Methods and compositions for treating cancer | |
| IL273959A (en) | Methods and preparations for the treatment of rare diseases | |
| IL276808A (en) | Preparations and methods for the treatment of cancer | |
| GB2578539B (en) | Compositions and methods for preventing or treating muscle conditions | |
| AU2018297285A1 (en) | Compositions and methods for treating or preventing endocrine FGF-linked diseases | |
| RS67299B1 (sr) | Kompozicije za lečenje i/ili prevenciju bolesti agregacije proteina | |
| IL287796A (en) | Preparations and methods for the treatment of diseases mediated by ATPase | |
| IL280413A (en) | Bismuth-thiol preparations and wound treatment methods | |
| ZA202101362B (en) | Compositions and methods for treating the eye | |
| SG11202102442WA (en) | Methods and compositions for preventing and treating atherosclerosis and related diseases | |
| ZA202100703B (en) | Compositions and methods for treating inflammasome related diseases or conditions | |
| IL285886A (en) | Preparations and methods for the treatment of laminopathy | |
| SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
| SG11202012070YA (en) | Methods and compositions for preventing or treating tissue calcification | |
| SG11202012435UA (en) | Compositions and methods for treating cancer | |
| IL275767A (en) | Compositions and methods for treating metabolic diseases | |
| SG11202003539VA (en) | Compositions and methods for treating liberibacter diseases and other bacterial diseases | |
| ZA202101342B (en) | Compositions and methods for treating the eye | |
| IL285796A (en) | Methods and preparations for the treatment of cancer | |
| IL269743A (en) | Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions | |
| KR102316727B9 (ko) | 아토피성 질환 예방 또는 치료용 약학적 조성물 | |
| EP3768095A4 (en) | Compositions and methods for treating diarrheal diseases | |
| GB202001422D0 (en) | Compositions and methods for preventing or treating nephrolithiasis | |
| ZA202101361B (en) | Compositions and methods for treating the eye | |
| ZA202101360B (en) | Compositions and methods for treating the eye |